Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Oncol. Jul 24, 2024; 15(7): 848-858
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.848
Table 1 Demographics and clinical characteristics of germline BRCA-positive and BRCA-negative breast cancer
gBRCA1
Positive
Negative
Total, n (%)15 (26.3)42 (73.7)
Age in yr at diagnosis, mean ± SD42.1 ± 1145.3 ± 8.7
Positive family history, n (%)8 (53.3)16 (38.1)
First-degree relative, n (%)8 (53.3)9 (21.3)
Non-first-degree relatives, n (%)4 (26.6)11 (26.1)
H/o IVF & Rx, n (%)00
H/o hormone Rx, n (%)1 (6.6)4 (9.5)
ECOG PS at diagnosis2, n (%)
    013 (86.7)40 (95.2)
    12 (12.3)2 (4.8)
Histology at diagnosis, n (%)
    Invasive ductal carcinoma12 (80) 35 (83.3)
    Invasive lobular carcinoma1 (6.6)4 (9.5)
Grade at diagnosis, mean ± SD3 ± 0.62 ± 0.7
Stage at diagnosis, n (%)
    11 (6.6)0
    27 (46.6)21 (50)
    34 (26.6)13 (31)
    43 (20)8 (19)
Categories3, n (%)
    HER2-positive 4 (26.6)12 (28.7)
    Triple-negative3 (20)8 (19.0)
    HR-positive and HER2-negative6 (40)15 (35.7)
    HR-positive and HER2-positive3 (20)6 (14.3)
Table 2 Clinical outcomes of poly (ADP-ribose) polymerase inhibitor therapy in BRCA gene-positive breast cancer and homologous recombination deficiency-positive ovarian cancer patients
Cancer type
Patient
Stage
Response change to PARPi
Duration of PARPi
PARPi status at end of study
BRCA+ breast cancer, 5/15 (33.3%)1IICR–DF13 months+On Rx
21IIPR–PR40 daysStopped
3IIICR–DF17 months+On Rx
4IVPR–PR5 monthsStopped
52IVPR7 monthsStopped
HRD+ ovarian cancer, 4/6 (66.6%)1IIIPR–DF15 months+On Rx
2IVCR–DF13 months+On Rx
3IVSD–PRF20 months+On Rx
4IVCR–DF25 months+On Rx
Table 3 Demographic and clinical characteristics of homologous recombination deficiency-positive and -negative ovarian cancer
Characteristic
HRD-positive
HRD-negative
Total, n (%)6 (24)19 (76)
Age years at diagnosis, mean ± SD56.5 ± 1152.5 ± 13
Positive family history, n (%)05 (26.3)
ECOG PS at diagnosis, n (%)
    05 (83.3)17 (89.4)
    11 (16.7)1 (5.3)
    201 (5.3)
Histology, n (%)
    Serous 5 (83.3)9 (47.3)
    Endometrioid/mucinous/clear cell 1 (16.7)5 (26.3)
    Mixed05 (26.3)
Grade of cancer, mean ± SD4 ± 04 ± 0.9
Stage of cancer, n (%)
    11 (16.7)2 (10.5)
    200
    32 (33.3)11 (58)
    43 (50)6 (31.5)
Surgical Rx, n (%)6 (100)17 (89.5)
    Primary2 (33.3)12 (63.1)
    Interval4 (66.7)5 (26.4)